Business Wire

DNA Script Enables Same-day q/dPCR from Design to Results with Launch of Next-generation SYNTAX Kits at AGBT

Share

Today at the Advances in Genome Biology and Technology (AGBT) Conference, DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, announced the launch of the industry’s first solution to enable same-day turnaround for custom q/dPCR assays with a new generation of kits for the SYNTAX System to print both primers and probes in hours. This announcement comes two days ahead of their AGBT presentation on Wed, June 8, at 2:55pm EDT, where their founders will review recent data showcasing the new applications enabled for the SYNTAX System.

For the first time since the introduction of PCR in 1984, labs will be able to design and print q/dPCR assays, directly on their benchtops, in as little as 8 hours. The combination of increased performance, just 15 minutes of set up, rapid synthesis turnaround and complete workflow control provides labs the best value for custom modified oligos. The new kits are designed to accelerate assay development workflows in genomics, in particular for q/dPCR, NGS, ISH and FISH.

“We see this product launch as a game-changer, enabling SYNTAX customers to be done with their assays before others have even started. More than ever before, science and innovation are in a race for results, whether it is an upcoming scientific publication, a new diagnostic test or even a vaccine. Researchers need to get there faster, and we will help them to get there first,” said DNA Script CEO and co-founder Thomas Ybert, Ph.D. “With an in-house, benchtop SYNTAX System and these new kits, we are enabling our customers to replace a complex synthesis workflow with a single instrument that takes the iterative assay development process from months down to days.”

This latest generation of kits launches several new capabilities on the SYNTAX Platform:

  • Print oligos up to 80 nt in length
  • Synthesize hydrolysis probes and primers in the same run, in as little as 8 hours
  • Print oligos at a higher yield and concentration (≥7 µM and ≥600 pmol)
  • Label probes with fluorophores, quenchers and biotin

DNA Script’s SYNTAX Platform offers researchers dramatic time savings, printing primers and probes in 8 - 12 hours, as well as the best value per assay compared to leading third-party oligo service solutions in the marketplace. Early adopters of the SYNTAX platform have already leveraged on-demand synthesis to eliminate bottlenecks in the development of assays for biothreat detection, assays for rapid-response to viral outbreaks, and novel vaccines and therapies.

“The SYNTAX System is a game changer for preclinical CRO labs like ours. For the biomarker identification and gene expression profiling we do, we spend thousands of dollars a month on primers and probes and end up waiting for them to be synthesized and shipped. Having SYNTAX on site cuts our assay turnaround time, decreases our cost per assay by ~30%, and enables our lab to optimize expression assays more quickly--all of which significantly improves our bottom line," said Jonathan Wray, Managing Partner at DC3 Therapeutics. “The ease of use and excellent service and support from DNA Script enabled us to be up and running with the SYNTAX System in no time.”

As a Bronze sponsor, DNA Script is hosting a hospitality room in the Jade-Lexington Suite throughout the duration of the AGBT Conference, where attendees can see the SYNTAX System in action, demonstrating the speed of synthesizing probes and primers in-house with plug-and-play ease and automation. One-on-one demonstrations can be scheduled in advance.

DNA Script presentations at AGBT include:

  • Podium Presentation: Same-Day Enzymatic DNA Synthesis: Now Print Primers and Labeled Probes Using the SYNTAX System
    Presenters: Ybert and DNA Script CTO and co-founder Xavier Godron, Ph.D.
    Date & Time: Wed, June 8, 2:55 - 3:15 pm EDT
    Location: Main Session - Floridian Salons A-L
  • Poster Presentation (#517): Enzymatic DNA Synthesis (EDS) Allows Rapid Access to Synthetic Oligos to Produce Expression Vectors for SARS-CoV-2 Spike Variants
    Presenters: Benoit Derrien, Ph.D., Application Project Leader, DNA Script
    Date & Time: Tues, June 7, 1:30 - 3:00 pm EDT
    Location: Bonnet Creek Ballroom Salon VII-XII
  • Poster Presentation (#540): Access to Synthetic Oligos Produced by Enzymatic DNA Synthesis (EDS) Accelerated the Development of Candida glabrata Mutants During the COVID-19 Pandemic
    Presenters: Colin Clairet, Ph.D., Post-doctoral Researcher, Institut Pasteur
    Date & Time: Wed, June 8, 4:40 pm - 6:10 pm EDT
    Location: Bonnet Creek Ballroom Salon VII-XII

“Since we released the world’s first commercial access to Enzymatic DNA Synthesis via the SYNTAX Platform in the summer of 2021, we have made a number of improvements to advance benchtop DNA printing,” said Ybert. “Given the many applications, and the urgent need to perform them quickly, in-house DNA printing on demand is becoming one of the most important technologies of the 21st century.”

About DNA Script

Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, enabling this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System. By putting DNA synthesis back in the lab, DNA Script aims to transform life sciences research through innovative technology that gives researchers unprecedented control and autonomy. www.dnascript.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press contacts in the US
Seismic

Valerie Enes
415-692-6799
valerie@teamseismic.com

DNA Script Contact
Joleen Rau
joleen.rau@dnascript.co
publicrelations@dnascript.co

Press contact in Europe
ALIZE RP

Caroline Carmagnol
06 64 18 99 59
caroline@alizerp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Quectel Announces Industry First 5G-Advanced 3GPP R18 Automotive-Grade Cellular Module, Delivering Unmatched Performance and Reliability2.1.2026 19:00:00 EET | Press release

Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the world's first 5G-advanced (5G-A) automotive-grade cellular module, the AR588MA, establishing it as the industry's highest-performing and most reliable wireless communication product for vehicles. Based on MediaTek's latest-generation MT2739 platform, the AR588MA supports 5G-A communication technology and is the world's first to comply with the 3GPP R18 standard protocol. The module also features both NB-NTN and NR-NTN satellite communication capabilities, supports Dual SIM Dual Active (DSDA) technology, offering improved stability and reliability on cellular connections and includes intelligent driving scenario recognition. Designed in compliance with the AEC-Q104 Grade 2 automotive standard, it delivers faster, more stable connectivity and reliable security for in-vehicle communication and benefiting the on-roof applications like smart antenna for automotive with higher temperatu

Interactive Brokers’ Individual and Hedge Fund Clients Outperformed the S&P 500 on Average in 20252.1.2026 17:00:00 EET | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced that its clients outperformed the S&P 500 Index in 2025, reflecting the benefits of cost efficiency, execution quality, and broad access to global markets. In 2025, Interactive Brokers’ individual clients achieved an average return of 19.20%, compared with the 17.9% return of the S&P 500 Index. During the same period, Interactive Brokers’ hedge fund clients achieved an average return of 28.91%, outperforming the index by approximately 11 percentage points. These results demonstrate how Interactive Brokers helps enhance client returns across the investment lifecycle. Global market access enables clients to allocate capital across various regions and asset classes, while lower trading and financing costs, along with efficient execution, help IBKR investors retain more of their returns over time. “Investment returns are not just about picking the right trades. They are influenced by the costs you pa

Aeromexico Repeats as Most On-Time Global Airline; Qatar Airways Claims Platinum Award2.1.2026 12:00:00 EET | Press release

Aeromexico maintained a 90.02% on-time performance to claim the world's most on-time global airline title for the second consecutive year, according to Cirium's 2025 On-Time Performance Review released today. The Mexican carrier becomes only the second airline to achieve consecutive global wins since Cirium launched the program in 2009, operating 188,859 flights across 23 countries while maintaining industry-leading schedule reliability. Aeromexico Holds Global Lead; Regional Champions Crowned Aeromexico secured the global airline title with 90.02% on-time performance, holding off strong competition from Saudia in second place with 86.53% and SAS with 86.09% in third. The margin between first and third place was 3.93 percentage points, reflecting the strong performance of Aeromexico in 2025. Regional winners included: North America: Delta Air Lines won for the fifth consecutive year with 80.90% on-time performance Europe: Iberia Express (International Airlines Group) defended its title

Samsung Bioepis Begins Commercialization of BYOOVIZ ® , Biosimilar to Lucentis (Ranibizumab), in Europe2.1.2026 09:00:00 EET | Press release

Samsung Bioepis Co., Ltd. today announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to Samsung Bioepis, and BYOOVIZ will now be available as a Samsung Bioepis brand across multiple European countries. “This is a significant milestone for Samsung Bioepis as the company continues to strengthen its presence in Europe by expanding its portfolio of directly commercialized products. Leveraging the past three years of experience with EPYSQLI (eculizumab) and the newly launched OBODENCE (denosumab) and XBRYK (denosumab) in Europe, we will continue on our journey to become a fully integrated biopharmaceutical company with end-to-end capabilities from development to commercialization,” said Antonio Rito, Vice President and Head of Europe, at Samsung Bioepis. “We will work closely with payers and healthcare professionals to e

Cessna Citation Ascend Enters Into Service, Redefining Performance and Cabin Experience in the Midsize Business Jet Market31.12.2025 16:00:00 EET | Press release

The Cessna Citation Ascend achieved a major milestone as the first retail customer took delivery of the midsize business jet on Tuesday, December 30, marking the aircraft’s entry into service. Announced in 2023 the aircraft boasts an entirely new cockpit, improved performance and a luxurious flat floor cabin. The Citation Ascend received type certification from the Federal Aviation Administration (FAA) in November 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251231586042/en/ Cessna Citation Ascend enters into service, redefining performance and cabin experience in the midsize business jet market. (Photo credit: Textron Aviation) The Cessna Citation Ascend is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “The first Citation Ascend delivery underscores Textron Aviation’s commitment to redefining the midsize segment with an aircraft that blends innovation, efficiency and unmatch

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye